SCHEMBL4042940

SCHEMBL4042940

O=C(NC1CCCCC1)C(C1CCCCC1)C1(c2ccccc2)Nc2ccccc2N1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
KMT2A Q03164 2/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 1/20 0.43
EPHX1 P07099 4/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 3/20 0.43
EPHX2 P34913 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
METAP2 P50579 3/20 0.42
METAP1 P53582 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043049 0.91 SMN1; SMN2 (0.46) TSHRSMN1; SMN2KMT2AHTTMEN1
SCHEMBL4039101 0.90 NR1H4 (0.44) TSHRSMN1; SMN2KMT2AHTTMEN1
SCHEMBL4042732 0.90 NR1H4 (0.44) TSHRSMN1; SMN2KMT2AHTTMEN1
SCHEMBL4040005 0.90 KMT2A (0.43) TSHRSMN1; SMN2KMT2AHTTMEN1
SCHEMBL4037453 0.90 EPHX1 (0.43) TSHRSMN1; SMN2KMT2AHTTMEN1
SCHEMBL4037602 0.90 EPHX1 (0.50) TSHRSMN1; SMN2HTTEPHX1RAB9A
SCHEMBL4043896 0.88 HTT (0.42) TSHRSMN1; SMN2KMT2AHTTMEN1
SCHEMBL4040671 0.88 NPC1 (0.45) TSHRSMN1; SMN2KMT2AHTTMEN1
SCHEMBL4041199 0.88 SMN1; SMN2 (0.47) TSHRSMN1; SMN2KMT2AHTTMEN1
SCHEMBL4041915 0.88 SMN1; SMN2 (0.42) TSHRSMN1; SMN2KMT2AHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed